SCHEMBL5013602

SCHEMBL5013602

CC(C)(C)OC(=O)NCc1ccnc(C(N)=O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.53
BRD4 O60885 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
NAMPT P43490 2/20 0.44
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
KDM4A O75164 1/20 0.41
GLS O94925 2/20 0.41
NR1H4 Q96RI1 1/20 0.41
CYP3A4 P08684 1/20 0.41
BRD9 Q9H8M2 1/20 0.41
BAZ2B Q9UIF8 1/20 0.41
BAZ2A Q9UIF9 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
GFER P55789 1/20 0.40
HSD17B10 Q99714 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
CA12 O43570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1698559 0.88 L3MBTL1 (0.47) GRM2BRD4L3MBTL1KDM4ELMNA
SCHEMBL29693623 0.88 L3MBTL1 (0.47) GRM2BRD4L3MBTL1KDM4ELMNA
SCHEMBL3121652 0.85 CA1 (0.45) BRD4KDM4ECYP3A4GFERCA12
SCHEMBL337888 0.84 L3MBTL1 (0.48) GRM2BRD4L3MBTL1NAMPTKDM4A
SCHEMBL8117393 0.83 L3MBTL1 (0.47) GRM2BRD4L3MBTL1NAMPTKDM4A
SCHEMBL15871964 0.82 BRD4 (0.49) GRM2BRD4L3MBTL1NAMPTKDM4A
SCHEMBL30399922 0.82 L3MBTL1 (0.49) GRM2BRD4L3MBTL1NAMPTKDM4A
SCHEMBL10163771 0.82 L3MBTL1 (0.49) GRM2BRD4L3MBTL1NAMPTKDM4A
Hydrochloric Acid SCHEMBL29868035 0.82 L3MBTL1 (0.46) GRM2BRD4L3MBTL1NAMPTKDM4A
SCHEMBL14200095 0.81 LMNA (0.52) GRM2BRD4L3MBTL1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL GRM2 3774/4885BRD4 2355/4885L3MBTL1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.